Message from the Guest Editor

Dear Colleagues,

Gene therapy is defined as introducing genetic information for therapeutic purposes. Besides conventional usage, such as protein-replacement therapies, in many medical fields, the applications have been widely expanding from vaccination against infectious diseases or cancer, and "gene" editing using the cutting-edge technologies of ZFN, TALENs, and CRISPR–Cas9. Cell therapy combined with ex vivo gene introduction is also an exciting field. The Special Issue of Pharmaceutics on “New paradigm of gene therapy” will address diverse areas related to gene therapy, including nucleic acids preparation (DNA, RNA), delivery systems, administration technique, and proof-of-concept studies using animal models. Original research papers or review articles on any of these aspects are welcomed for this Special Issue.

Keiji Itaka
Guest Editor

Author Benefits

- **Open Access**: free for readers, with publishing fees paid by authors or their institutions.
- **High visibility**: citations available in PubMed, full-text archived in PubMed Central. Covered by Scopus: papers published between 2013 and 2015 have been cited 3.73 times, on average, in 2016 (CiteScore 2016).
- **Rapid publication**: manuscripts are peer-reviewed and a first decision provided to authors approximately 31 days after submission; acceptance to publication is undertaken in 8 days (median values for papers published in this journal in 2016).